Small-Cell Lung Cancer | Disease Landscape & Forecast | G7 | 2020
For decades, the treatment landscape of small-cell lung cancer (SCLC) has been dominated by chemotherapy or chemoradiotherapy. In 2018, BristolMyers Squibb’s Opdivo became the first immune checkpoint inhibitor to be approved in the United States for extensive-stage SCLC. In 2019, Merck & Co.’s Keytruda was approved in the same setting as Opdivo in the United States and Roche / Genentech / Chugai’s Tecentriq was approved in combination with chemotherapy as a treatment for extensive-stage SCLC in the seven major markets. In 2020, AstraZeneca’s Imfinzi was approved in the same setting as Tecentriq across all major markets, and the FDA approval of PharmaMar’s Zepzelca marked the entry of a novel chemotherapy agent for patients. However, despite the flurry of approvals, a significant unmet need remains for more efficacious therapeutic options. Despite the comparatively small market size, the modest late-phase pipeline looks set to further revolutionize SCLC treatment algorithms, with other novel agents enetering late-phase development such as Roche’s anti-TIGIT MAb tiragolumab and Ipsen/Servier’s liposomal irinotecan agent Onivyde.
Questions Answered
- How is SCLC managed, and how will the treatment paradigm evolve?
- What are the sizes of the drug-treatable SCLC populations and how will drug-treatment rates change over time?
- How will the recent approvals of immune checkpoint inhibitors for extensive-stage SCLC impact the market?
- What are the major unmet needs, and how will key emerging therapies shape the SCLC market over the ten-year forecast period?
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Scope:
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
Primary research: 19 country-specific interviews with experts and 210 country-specific surveys of medical oncologists treating SCLC.
Epidemiology: Diagnosed incidence of SCLC by country (segmented by limited-stage and extensive-stage disease).
Population segments in market forecast: Limited-stage, first-line extensive stage, second line, and third line.
Emerging therapies: Phase I/II: 11 drugs; Phase III: 6 drugs.
